文献速递心血管技术与安全PETMR

心脏 68Ga-FAPI-4 PET/MRI 在扩张型心肌病中的可行性研究

Hybrid Cardiac 68Ga-FAPI-4 PET/MRI in Dilated Cardiomyopathy: A Feasibility and Pilot Study.
PubMed 文献 · Radiology · 2026-01-01

本研究前瞻性纳入 37 例受试者(25 例非缺血性扩张型心肌病患者、健康对照及肿瘤对照),采用 3.0T PET/MRI 一体化心脏 68Ga-FAPI-4 成像,同时评估心脏结构、功能与分子重塑。结果显示 68% 的扩张型心肌病患者心肌 FAPI 摄取升高,FAPI PET 参数对鉴别扩张型心肌病与对照具有良好诊断效能(AUC 0.83–0.92),且 SUVmax 与左心室容积、射血分数及心肌纤维化指标相关。

要点

  • 扩张型心肌病患者 FAPI 摄取范围可超过 LGE 范围,提示其反映更早期的分子重塑
  • FAPI PET 参数与左心室重构及心肌纤维化指标相关,可用于疾病严重度辅助判断
  • 一体化 PET/MRI 流程约 32 分钟完成心脏 MRI 采集,具备临床应用可行性

核心结论

  • 心脏 68Ga-FAPI-4 PET/MRI 能够同步实现非缺血性扩张型心肌病的分子与结构成像

研究设计与样本

  • 前瞻性研究,纳入 37 例受试者,中位年龄 53 岁(IQR 48–58 岁),其中男性 32 例、女性 5 例
  • 研究对象为扩张型心肌病患者、无心血管疾病的肿瘤对照及健康对照
  • 采用 3.0T PET/MRI 一体化系统,同步采集 FAPI PET 与心脏 MRI,包括电影序列、T1/T2 mapping 和 LGE
  • 肿瘤对照组采用 68Ga-FAPI-4 PET/CT 进行对照比较

关键影像表现/征象

  • 68%(17/25)的扩张型心肌病患者显示心肌 FAPI 摄取升高
  • 在 LGE 与 FAPI 均阳性的病例中,73%(8/11)的 FAPI 摄取范围超过 LGE 范围
  • 健康对照及肿瘤对照受试者中心肌 FAPI 摄取均缺失

诊断标准与关键数值

  • FAPI PET 平均标准化摄取值(SUVmean)鉴别扩张型心肌病与对照的 AUC 为 0.92(95% CI: 0.82, 0.99)
  • FAPI PET 最大标准化摄取值(SUVmax)的 AUC 为 0.91(95% CI: 0.81, 0.98)
  • 靶本底比值(TBR)的 AUC 为 0.83(95% CI: 0.69, 0.94)
  • SUVmax 与左心室舒张末期容积指数呈正相关(R = 0.47;P = .02),与左心室射血分数呈负相关(R = -0.47;P = .02)
  • SUVmax 与 T1 值(R = 0.21)、T2 值(R = 0.30)及细胞外容积(R = 0.36)均呈正相关(均 P < .001)

临床应用与阅片要点

  • 心脏 MRI 平均采集时间为 32.0 ± 6.0 分钟,扫描间总占用时间为 37.6 ± 6.6 分钟,提示流程时间效率可接受
  • FAPI 摄取范围可超过 LGE 范围,阅片时应注意识别 LGE 阴性区域中可能存在的 FAPI 异常摄取
  • SUVmax 升高提示更明显的左心室重构与收缩功能受损,可用于报告中的定量参考

局限性

  • 本研究样本量为 37 例,属于可行性与初步研究,样本规模有限
  • 未提供长期随访数据,FAPI 摄取与临床预后的关系尚不明确

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background Cardiac gallium 68-labeled fibroblast activation protein inhibitor (FAPI)-4 (68Ga-FAPI-4) PET/MRI allows simultaneous assessment of cardiac tissue characteristics, function, and molecular remodeling in myocardial diseases. An integrated workflow for nonischemic dilated cardiomyopathy (DCM) has yet to be developed. Purpose To evaluate the feasibility and performance of a time-efficient cardiac 68Ga-FAPI-4 PET/MRI protocol in participants with DCM. Materials and Methods In this prospective study, participants with DCM and healthy controls were enrolled for hybrid 68Ga-FAPI-4 PET/MRI. Additionally, comparison was made with a further control group of oncology patients without cardiovascular disease who underwent 68Ga-FAPI-4 PET/CT. A 3.0-T PET/MRI system was used, enabling coregistered FAPI PET and cardiac MRI, including cine imaging, T1 and T2 mapping, and late gadolinium enhancement (LGE). Myocardial FAPI uptake was quantified, and correlations with cardiac MRI and clinical markers were assessed. Receiver operating characteristic analysis was used to evaluate the diagnostic performance of FAPI PET metrics for distinguishing participants with DCM from controls. Results This study included 37 participants (median age, 53 years [IQR, 48-58 years]; 32 male and five female). All participants completed a hybrid PET/MRI protocol, with mean cardiac MRI scan acquisition time and scanner room time of 32.0 minutes ± 6.0 (SD) and 37.6 minutes ± 6.6, respectively. Of the participants with DCM, 68% (17 of 25) showed elevated myocardial FAPI uptake, exceeding LGE extent in 73% of LGE- and FAPI-positive cases (eight of 11). In contrast, myocardial FAPI uptake was absent in healthy controls and oncology participants. Excellent diagnostic performance for DCM was observed for FAPI PET mean standardized uptake value (area under the receiver operating characteristic curve [AUC], 0.92 [95% CI: 0.82, 0.99]), maximum standardized uptake value (SUVmax) (AUC, 0.91 [95% CI: 0.81, 0.98]), and target to background ratio (AUC, 0.83 [95% CI: 0.69, 0.94]). SUVmax showed a positive correlation with left ventricular (LV) end-diastolic volume index (R = 0.47; P = .02) and a negative correlation with LV ejection fraction (R = -0.47; P = .02). SUVmax was positively correlated with T1 and T2 values (R = 0.21 and 0.30, respectively) and extracellular volume (R = 0.36) (all P < .001). Conclusion Hybrid cardiac 68Ga-FAPI-4 PET/MRI successfully enabled simultaneous molecular and structural imaging for nonischemic DCM. Clinical trial registration no. ChiCTR1800017058 © RSNA, 2026 Supplemental material is available for this article. See also the editorial by Kusmirek and Johnson in this issue.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Zhou, Lin, Huang, et al. Hybrid Cardiac 68Ga-FAPI-4 PET/MRI in Dilated Cardiomyopathy: A Feasibility and Pilot Study. Radiology. 2026. PMID: 42301017. doi:10.1148/radiol.252706

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。